Skip to content
OpenCapital
Get started

OS Therapies OSTX Proceeds From Related Party Debt

Proceeds From Related Party Debt at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$102.23M—

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M—
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K—
Free cash flow-$3.7M—

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M—

Returns & leverage

See full
Return on equity470%—
Debt / equity-1.8×—
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromRelatedPartyDebt.

The official record: OS Therapies’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's proceeds from related party debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's proceeds from related party debt?
OS Therapies (OSTX) reported proceeds from related party debt of $33.55K in Q4 2025.
How has OS Therapies's proceeds from related party debt changed year-over-year?
OS Therapies's proceeds from related party debt decreased by 39.8% year-over-year, from $55.72K to $33.55K.
What does proceeds from related party debt mean?
Cash inflows generated from debt financing arrangements provided by insiders, major shareholders, or affiliated entities. This metric is a key indicator of liquidity support from parties with a vested interest in the company's survival.